50% off Premium Yearly
Cineplex IncCGX.TOBUYMay 01, 2013Stock price when the opinion was issued
As of Jun 19, 2026. Market Open.
Revenue growth is coming back a bit, with lower comparables from last year helping the year-over-year figures. Its debt levels are high, with net debt of $1.9B, and a net debt/EBITDA of 6.8X. Interest costs are $137M (last 12 months) and these will likely rise a bit with higher rates. 12-month cash flow was $116M and therein lies the problem. The debt is mostly due in the next five years. With attendance back, and a decent film slate, bankruptcy is becoming less of a concern, but it is still hard to paint a really positive picture here because of the leverage.
It is somewhat cheap (0.4X forward sales), but also has a fairly high forward P/E of 20.2X. It could become a takeover target, however, we would not place a high level of probability on that at these current levels.
Unlock Premium - Try 5i Free
Cineplex remains a recovery story, and its beta of 2.88 signals more risk than usual. It rose 10% in Q1, but the chart was choppy. So, consider Cineplex a partial buy. After all, Covid didn’t kill cinema-going, as some expected, but deferred it. We still love the big screen. Read Dark horses: Nuvei, Cineplex, Boralex for our full analysis.
A huge fan of this company. At a 52-week high which kind of concerns him, but it literally just keeps going up. The last 6 months box office has not been terrific which is an industry problem, not a Cineplex problem. However, there are some really big names coming in and people are going to pay extra money to see them in Cineplexes. They are also competing with Netflix with their ultraviolet program. Very well managed company. Almost 4% dividend yield.